Does Rallies show Form 4 insider transactions for ROIV?

Yes. Rallies tracks ROIV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ROIV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ROIV. It does not provide personalized investment advice.

ROIV (Roivant Sciences Ltd. Common Shares) Stock Analysis - Insider Trades

Roivant Sciences Ltd. Common Shares (ROIV) is a publicly traded Healthcare sector company. As of May 20, 2026, ROIV trades at $32.12 with a market cap of $20.43B and a P/E ratio of -118.03. ROIV moved +13.86% today. Year to date, ROIV is +28.64%; over the trailing twelve months it is +160.24%. Its 52-week range spans $8.73 to $30.33. Analyst consensus is strong buy with an average price target of $35.31. Rallies surfaces ROIV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ROIV stock inside the company?

Recent ROIV insider activity includes Venker Eric sold 200.00K, Gline Matthew sold 289.77K, Humes Jennifer sold 13.54K, Fitzgerald Meghan sold 70.00K, and Venker Eric sold 200.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ROIV Key Metrics

Key financial metrics for ROIV
Metric	Value
Price	$32.12
Market Cap	$20.43B
P/E Ratio	-118.03
EPS	$-0.24
Dividend Yield	0.00%
52-Week High	$30.33
52-Week Low	$8.73
Volume	7.05M
Avg Volume	0
Revenue (TTM)	$29.05M
Net Income	$-356.73M
Gross Margin	0.00%

Recent ROIV Insider Trades

Venker Eric sold 200.00K (~$5.92M) on Apr 20, 2026.
Gline Matthew sold 289.77K (~$8.45M) on Apr 16, 2026.
Humes Jennifer sold 13.54K (~$384.07K) on Apr 8, 2026.
Fitzgerald Meghan sold 70.00K (~$1.92M) on Mar 26, 2026.
Venker Eric sold 200.00K (~$5.65M) on Mar 17, 2026.

Latest ROIV News

Roivant Sciences Q4 EPS Tops Forecast, $770M Settlement Drives 9.9% Stock Jump — May 20, 2026
IMVT-1402 Shows 72.7% ACR20; Roivant Secures $2.25B Moderna Settlement — May 20, 2026
Roivant climbs as investors refocus on $950M Moderna settlement cash due July 8 — Apr 30, 2026
Roivant climbs as $4.3B cash position and buybacks spotlight pipeline momentum — Apr 27, 2026
Roivant slides as insider-sale filings hit tape ahead of Q3 FDA brepocitinib decision — Apr 24, 2026

ROIV Analyst Consensus

8 analysts cover ROIV: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.31.

Common questions about ROIV

Who is trading ROIV stock inside the company?: Recent ROIV insider activity includes Venker Eric sold 200.00K, Gline Matthew sold 289.77K, Humes Jennifer sold 13.54K, Fitzgerald Meghan sold 70.00K, and Venker Eric sold 200.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ROIV?: Yes. Rallies tracks ROIV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ROIV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ROIV. It does not provide personalized investment advice.